Idera Pharmaceuticals resumed with an Overweight at JPMorgan. JPMorgan analyst Anupam Rama resumed coverage of Idera Pharmaceuticals with an Overweight rating and $15 price target following a period of restriction. Rama tells investors in a research note that Idera’s Q2 results highlighted its continued prioritization of IMO-2125 in oncology, and views IMO-2125 as an underappreciated asset at current levels. Looking ahead, Rama believes the TLR9 space is gaining increased interest, and says date to data for IMO-2125 are differentiated in PD-1 refractory metastatic melanoma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.